Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 6, 1997, Pages 255-260

  Muck W ^a   Ritter, W ^a   Ochmann, K ^a   Unger, S ^a   Ahr, G ^a   Wingender, W ^a   Kuhlmann, J ^a  

^a BAYER AG   (Germany)

Author keywords

Absorption; Bioavailability; Cerivastatin; HMG CoA reductase inhibitor; Intravenous, oral drug administration; Pharmacokinetics

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; HALF-LIFE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; MALE; PILOT PROJECTS; PYRIDINES; SPECTROMETRY, FLUORESCENCE; TABLETS;

EID: 1842338712     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Angerbauer R, Bischoff H, Steinke W, Ritter W 1994 BAY w 6228. Drugs Future 19: 537-541
2. Duggan DE, Vickers S 1990 Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab Dispos 22: 333-362
3. Frey R, Mazzu A, Ritter W, Heller AH, Kuhlmann J 1993 Safety and tolerability of rivastatin, a novel HMG-CoA reductase inhibitor, in phase-I single dose studies. Naunyn Schmiedebergs Arch Pharmacol 347 (Suppl): R30
4. Gibaldi M, Perrier D 1982 Pharmacokinetics (2nd ed). Marcel Dekker, New York
5. Heinzel G, Woloszczak R, Thomann P 1993 Topfit 2.0 - Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC, Dr. Karl Thomae GmbH, Schering AG (Germany), Gödecke AG. Fischer, Stuttgart
6. Hsu I, Spinler SA, Johnson NE 1995 Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolaemia. Ann Pharmacother 29: 743-759
7. Krol GJ, Beck GW, Ritter W, Lettieri JT 1993 LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 11: 1269-1275
8. Mazzu A, Lettieri J, Kaiser L, Frey R, Heller AH 1993 Ascending multiple dose safety, tolerability and pharmacokinetics of rivastatin in humans. Clin Pharmacol Ther 53: 230
9. Mazzu A, Lettieri J, Heller AH 1997 Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. Abstract accepted for the 68th Meeting of the European Atherosclerosis Society (EAS), May 7-10, Brügge, Belgium
10. Mück W, Ritter W, Ochmann K, Kuhlmann J 1997 Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Naunyn Schmiedeberg's Arch Pharmacol 355 (Suppl): R127
11. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 35: 261-264
12. Pedersen TR, Kjekshus J, Berg K et al 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
13. Radtke M et al 1997 Biotransformation and metabolic disposition of cerivastatin in humans. Drug Metab Dispos in preparation
14. Ritter W, Frey R, Krol G, Kuhlmann J 1993 Rivastatin single dose pharmacokinetics. Clin Pharmacol Ther 53: 210
15. Shepherd J, Cobbe SM, Ford I et al 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Msd 333: 1301-1307
16. Steinke W, Yamashita S, Tabei M, Ahr HJ, Beckermann B, Domdey-Bette A, Göller G, Schwarz T, Siefert HM 1996 Cerivastatin, a new inhibitor of HMG-CoA reductase. Pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 24 (Suppl 9): 1217-1237